Two crystallographers who retracted a Structure paper last year have retracted a study about a similar subject in the Proceedings of the National Academy of Sciences, for similar reasons.
Here’s the notice for the paper, which has been cited 23 times, according to Thomson Scientific’s Web of Knowledge: Continue reading PNAS retraction marks second for crystallography group
Dipak Das, the UConn red wine researcher charged by his institution with rampant misconduct that will likely lead to dozens of retractions, is evidently a 99%-er — when it comes to accuracy, that is.
According to a statement purportedly from his lawyer refuting those charges, Das claims, among other things, that the output from his lab was nearly perfect. He also has a lot to say about a 60,000-page report that the statement says he may not have actually downloaded.
We might note a lot more things about the letter, which we received from Bill Sardi, president of Longevinex, a resveratrol company which has worked with Das. Sardi has been sending Das defenses since the story broke; we posted some of them and Derek Lowe has posted parts of another. But here’s the letter, in its entirety: Continue reading Resveratrol researcher Dipak Das: My lab’s work was “99% correct”
Following an investigation by the State University of New York (SUNY) Upstate into the work of one of its neuroscientists, the Journal of Neurochemistry has retracted a 2007 paper.
The retraction notice is quite clear about why the paper is being withdrawn: Continue reading Journal of Neurochemistry retracts paper after SUNY Upstate medical school finds evidence of fraud
Today, without us having planned it, has become the day of retracted papers that found a new home.
This morning, we posted an item about a chimp “culture” paper that was retracted from Biology Letters after its authors found some errors, and then published, with corrections, in the Journal of Human Evolution. This afternoon, we bring you the news of a PLoS ONE paper on longevity genes that is the corrected version of a Science paper retracted last year: Continue reading Sebastiani and Perls longevity genes work finds a new home in PLoS ONE following Science retraction
The authors of a 2011 paper claiming that chimp “culture” has more to do with local habitats than with where the chimps live have retracted it after finding mistakes in their work.
Here’s the notice for the paper, “Variation in chimpanzee ‘culture’ is predicted by local ecology, not geography:” Continue reading Chimp ‘culture’ paper retracted after authors spot errors, now has home at another journal
In two unrelated cases, the Office of Research Integrity (ORI) has sanctioned a grad student and a pair of colleagues, one of whom plagiarized and the other allowed the intellectual theft to go unchecked.
We think the handling of these cases — both first noted briefly by The Chronicle of Higher Education — is worth noting.
Continue reading ORI roundup: Former SUNY grad student, two Kansas U researchers hit with sanctions
In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.”
Harvard’s David Sinclair went further, telling The New York Times that he didn’t know who Das was: Continue reading So how peripheral was Dipak Das’ resveratrol work, really?
Many Retraction Watch readers will now be familiar with the case of Dipak Das, the resveratrol researcher about whom the University of Connecticut issued a voluminous report yesterday — summary here — detailing 145 counts of data fabrication and falsification. This has been a fast-moving story, so we wanted to highlight a number of updates to our original post, and offer a few more.
First, we have confirmed with publisher Mary Ann Liebert this morning that Das has been relieved of his duties as co-editor in chief of Antioxidants & Redox Signaling. He had shared that post with Chandan Sen, and his name as been removed from the masthead of that journal. Here’s a statement from the publisher: Continue reading Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges
The University of Connecticut, in what clearly seems like an attempt to get ahead of damaging news, has announced an “extensive” investigation into research misconduct involving one of its scientists, Dipak K. Das.
According to a press release, the university has notified 11 journals that published Das’ work about the alleged fraud. One area of interest for Das, a government-funded professor of surgery and director of the Cardiovascular Research Center, has been resveratrol, a substance in red wine that has allegedly been linked to improved cardiac health.
The university touted some of his early efforts in this field.
[Please also see our update posted Thursday.]
Here’s what the release has to say: Continue reading UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case
The journal Cancer has issued an Expression of Concern about two lung cancer screening papers long dogged by doubt.
Last April, The Cancer Letter and The New York Times jointly published an investigation into the International Early Lung Cancer Action Program (I-ELCAP) run by Claudia Henschke and David Yankelevitz. Other researchers had already criticized the design and conclusions of that trial, but as the investigation noted, an October 2008 review of the study found that the researchers couldn’t find 90 percent of the subjects’ consent forms, an ethical no-no that jeopardizes as many as 135 papers.
Two papers published in Cancer, in 2000 and 2001, are among those studies, according to the notice (links added), which credits the Times and The Cancer Letter and notes that the journal has referred the case to Federal investigators: Continue reading Cancer issues expression of concern about two Henschke I-ELCAP lung cancer screening papers
